In vitro and in vivo studies showed that AML cell lines and primary AML samples carrying these mutations were addicted to NHE1 activation as evidenced by higher level of NHE1 phosphorylation and basal activities as well as increased sensitivities to NHE1 inhibition and knockdown. This evidence concerns the gene SLC9A1 and acute myeloid leukemia.